ABSTRACT

Objective

The appropriate treatments for the different molecular subgroups of medulloblastomas are challenging to determine. Hence, this study aimed to examine the expression profiles of long non-coding RNAs (LncRNAs) to determine a marker that may be important for treatment selection in these subgroups.

Methods

Changes in the expression of LncRNAs in the tissues of patients with medulloblastoma, which are classified into four subgroups according to their clinical characteristics and gene expression profiles, were examined via reverse transcription polymerase chain reaction. Moreover, there association with patient prognosis was evaluated.

Results

The expression levels of MALAT1 and SNGH16 were significantly higher in patients with group 3 medulloblastoma than in those with other subtypes. Patients with high expression levels of MALAT1 and SNGH16 had a relatively shorter overall survival than those with low expression levels.

Conclusions

Patients with group 3 medulloblastoma have a high MALAT1 level, which is associated with poor prognosis. Therefore, MALAT1 can be a new therapeutic target in medulloblastoma.

摘要

客观的

髓母细胞瘤不同分子亚群的适当治疗方法难以确定。因此，本研究旨在检查长非编码 RNA (LncRNA) 的表达谱，以确定可能对这些亚组中的治疗选择很重要的标记。

方法

通过逆转录聚合酶链反应检查髓母细胞瘤患者组织中 LncRNA 表达的变化，根据其临床特征和基因表达谱分为四个亚组。此外，评估了与患者预后的关联。

结果

MALAT1和SNGH16的表达水平在第3组髓母细胞瘤患者中显着高于其他亚型患者。MALAT1 和 SNGH16 高表达水平的患者与低表达水平的患者相比，总生存期相对较短。

结论

第 3 组髓母细胞瘤患者的 MALAT1 水平较高，与预后不良有关。因此，MALAT1可以成为髓母细胞瘤的新治疗靶点。